179 related articles for article (PubMed ID: 31359792)
1. Knockdown of lncRNA BLACAT1 reverses the resistance of afatinib to non-small cell lung cancer via modulating STAT3 signalling.
Shu D; Xu Y; Chen W
J Drug Target; 2020 Mar; 28(3):300-306. PubMed ID: 31359792
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice.
Chung CT; Yeh KC; Lee CH; Chen YY; Ho PJ; Chang KY; Chen CH; Lai YK; Chen CT
Pharmacol Res; 2020 Nov; 161():105183. PubMed ID: 32896579
[TBL] [Abstract][Full Text] [Related]
3. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
4. LncRNA BLACAT1 is involved in chemoresistance of non‑small cell lung cancer cells by regulating autophagy.
Huang FX; Chen HJ; Zheng FX; Gao ZY; Sun PF; Peng Q; Liu Y; Deng X; Huang YH; Zhao C; Miao LJ
Int J Oncol; 2019 Jan; 54(1):339-347. PubMed ID: 30387831
[TBL] [Abstract][Full Text] [Related]
5. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
[TBL] [Abstract][Full Text] [Related]
7. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
8. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
Ju ZS; Sun B; Bao D; Zhang XF
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788
[TBL] [Abstract][Full Text] [Related]
9. Secreted Phosphoprotein 1 (SPP1) Contributes to Second-Generation EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer.
Wang X; Zhang F; Yang X; Xue M; Li X; Gao Y; Liu L
Oncol Res; 2019 Aug; 27(8):871-877. PubMed ID: 30832751
[TBL] [Abstract][Full Text] [Related]
10. Celastrol acts synergistically with afatinib to suppress non-small cell lung cancer cell proliferation by inducing paraptosis.
Dai CH; Zhu LR; Wang Y; Tang XP; Du YJ; Chen YC; Li J
J Cell Physiol; 2021 Jun; 236(6):4538-4554. PubMed ID: 33230821
[TBL] [Abstract][Full Text] [Related]
11. Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Phan AN; Hua TN; Kim MK; Vo VT; Choi JW; Kim HW; Rho JK; Kim KW; Jeong Y
Oncotarget; 2016 Aug; 7(34):54702-54713. PubMed ID: 27419630
[TBL] [Abstract][Full Text] [Related]
12. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).
Codony-Servat C; Codony-Servat J; Karachaliou N; Molina MA; Chaib I; Ramirez JL; de Los Llanos Gil M; Solca F; Bivona TG; Rosell R
Oncotarget; 2017 Jul; 8(29):47305-47316. PubMed ID: 28521301
[TBL] [Abstract][Full Text] [Related]
13. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Lee Y; Wang Y; James M; Jeong JH; You M
Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
17. Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells.
Wang S; Liu C; Lei Q; Wu Z; Miao X; Zhu D; Yang X; Li N; Tang M; Chen Y; Wang W
Respir Res; 2021 May; 22(1):146. PubMed ID: 33980216
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway.
Li B; Yuan Z; Jiang J; Rao Y
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30420490
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361.
Wu X; Zheng Y; Han B; Dong X
Biomed Pharmacother; 2018 Mar; 99():832-838. PubMed ID: 29710482
[TBL] [Abstract][Full Text] [Related]
20. Palbociclib overcomes afatinib resistance in non-small cell lung cancer.
Nie H; Zhou X; Shuzhang D; Nie C; Zhang X; Huang J
Biomed Pharmacother; 2019 Jan; 109():1750-1757. PubMed ID: 30551429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
